ACST vs. VSTM, CLSD, PRPH, LFVN, TLSA, ETON, PMVP, ASRT, ORMP, and RLMD
Should you be buying Acasti Pharma stock or one of its competitors? The main competitors of Acasti Pharma include Verastem (VSTM), Clearside Biomedical (CLSD), ProPhase Labs (PRPH), LifeVantage (LFVN), Tiziana Life Sciences (TLSA), Eton Pharmaceuticals (ETON), PMV Pharmaceuticals (PMVP), Assertio (ASRT), Oramed Pharmaceuticals (ORMP), and Relmada Therapeutics (RLMD). These companies are all part of the "pharmaceutical preparations" industry.
Verastem (NASDAQ:VSTM) and Acasti Pharma (NASDAQ:ACST) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.
Verastem presently has a consensus price target of $25.69, indicating a potential upside of 548.67%. Acasti Pharma has a consensus price target of $6.00, indicating a potential upside of 119.85%. Given Acasti Pharma's higher probable upside, analysts clearly believe Verastem is more favorable than Acasti Pharma.
Verastem's return on equity of -13.18% beat Acasti Pharma's return on equity.
88.4% of Verastem shares are owned by institutional investors. Comparatively, 6.1% of Acasti Pharma shares are owned by institutional investors. 2.2% of Verastem shares are owned by insiders. Comparatively, 13.5% of Acasti Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Verastem received 287 more outperform votes than Acasti Pharma when rated by MarketBeat users. However, 70.52% of users gave Acasti Pharma an outperform vote while only 65.28% of users gave Verastem an outperform vote.
Acasti Pharma has lower revenue, but higher earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Acasti Pharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Verastem had 9 more articles in the media than Acasti Pharma. MarketBeat recorded 12 mentions for Verastem and 3 mentions for Acasti Pharma. Verastem's average media sentiment score of 0.94 beat Acasti Pharma's score of 0.03 indicating that Acasti Pharma is being referred to more favorably in the news media.
Verastem has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Acasti Pharma has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500.
Summary
Acasti Pharma beats Verastem on 8 of the 15 factors compared between the two stocks.
Get Acasti Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acasti Pharma Competitors List
Related Companies and Tools
